^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

Excerpt:
RECIST Response and Correlative Studies....As shown in Table 3 and Figure 3, 17 patients had a decrease in either the calcitonin or CEA level, and 11 patients had a decrease in both tumor markers….However, neither the timing nor the degree of tumor marker response significantly correlated with the degree or duration of RECIST response.
DOI:
10.1200/JCO.2009.25.0068